RPL7AA Antibody

Overview of RPL7 and RPL7A Antibodies

RPL7 and RPL7A are components of the 60S ribosomal subunit involved in mRNA translation and ribosome biogenesis. Antibodies against these proteins are widely used to study their roles in cellular growth, differentiation, and disease pathogenesis .

Western Blotting (WB)

• RPL7 Antibodies detect a ~29 kDa band in human cell lines (e.g., Raji, HeLa, A549) .

  • Recommended Dilution: 1:500–1:2000 .

  • Validation includes siRNA knockdown controls (e.g., U2OS cells treated with RPL7 siRNA show reduced signal) .

• RPL7A Antibodies (e.g., NBP3-15710) identify a 30–32 kDa band in MCF7, mouse liver, and rat kidney lysates .

  • Signal Optimization: 1:1000 dilution with 5s exposure under reducing conditions .

Immunohistochemistry (IHC)

• RPL7 Antibody (ab72550) labels human lung carcinoma tissues at 1:1000 dilution .

• RPL7A Antibody (15340-1-AP) detects breast cancer tissue with antigen retrieval (TE buffer pH 9.0) .

Immunoprecipitation (IP)

• RPL7 Antibodies immunoprecipitate endogenous RPL7 from HeLa lysates .

• RPL7A Antibodies isolate RPL7A from mouse kidney lysates using 0.5–4.0 µg antibody per 1–3 mg lysate .

Functional Insights

• RPL7:

  • Inhibits cell-free mRNA translation by binding G-rich structures in 28S rRNA .

  • Autoantigen in systemic lupus erythematosus (SLE) .

• RPL7A:

  • Regulates PI3K pathway-mediated cell growth .

  • Integral to freeze tolerance mechanisms in hibernating mammals .

Disease Associations

• Both proteins are dysregulated in cancers (e.g., breast, lung) .

• RPL7 interacts with RPL13 and RPL10A to modulate protein synthesis in tumor microenvironments .